<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01904266</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00028824</org_study_id>
    <nct_id>NCT01904266</nct_id>
  </id_info>
  <brief_title>Paravertebral Blocks for Breast Cancer Surgery</brief_title>
  <official_title>Combined General Anesthesia Plus Paravertebral Block Versus General Anesthesia Plus Opioid Analgesia for Breast Cancer Surgery: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project intends to look at the effect that a certain type of freezing
      injection, called a paravertebral block, has on the pain after an operation for breast
      cancer, the amount of pain relief that is needed and the side effects from this pain relief.
      The hypothesis is that the paravertebral block, in combination with a general anesthetic will
      reduce both pain scores and the amount of strong pain killers (opioids) that is needed. This
      will reduce the side effects of the pain killers such as nausea and vomiting.

      This will be assessed by comparing it a general anesthetic with pain killers given through
      the intravenous (IV) as is routine practice. Patients requiring breast cancer surgery, who
      agree to be involved in the trial, will be randomly allocated into two groups: both groups
      will receive a block, then a standardised and optimised general anesthetic. In one group
      however the block is simply a small injection under the skin (a sham block), whereas the
      other group will receive a proper paravertebral block prior to this. Both groups will receive
      opioids as necessary, depending on both their bodies reaction during the surgery and their
      pain scores when they wake up.

      The paravertebral block is a very safe procedure with a very low side effect profile, and
      many studies have shown a benefit in breast cancer surgery. The investigators would like to
      assess this in our own practice. The block is normally inserted under some light sedation,
      with freezing into the skin initially. It is normally very well tolerated. The sham block
      will also be performed under light sedation and freezing into the skin. The patients will not
      be able to tell whether they are having the sham block or the paravertebral block, because
      both are very well tolerated. There are no potential complications from the sham block.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Surgery for breast cancer can lead to a number of issues in the perioperative
      period. Both acute and chronic post-surgical pain are commonly encountered problems, with
      evidence that the degree of acute pain influences the likelihood of chronic pain.
      Post-operative nausea and vomiting (PONV) are also common, given the predominantly female
      surgical population and the requirement for opioid analgesia.

      Paravertebral block (PVB) is an effective means of providing analgesia for mastectomy. A
      recent meta-analysis5 suggested that there is considerable evidence that paravertebral blocks
      with or without a general anesthetic (GA) provide superior post-operative analgesia to breast
      surgery operations done with a GA alone. There is also a reduced need for rescue analgesia
      and reduced opioid-related side effects. The results of this meta-analysis may be influenced
      by publication bias, and the results are difficult to interpret because the lack of
      standardisation of technique (single level injection, multi-level injection or continuous
      blockade via a catheter inserted into the paravertebral space) and the variety of the type
      and dosage of the local anesthetics used for the PVB. The meta-analysis does suggest that PVB
      is an effective technique for mastectomy with a minimal complication rate.

      In our institution, the most common form of analgesia for mastectomy patients is systemic
      opioid analgesia. However, in the last two years, single level PVBs have been used with
      increasing frequency and reliable success. This is due in part to the use of
      ultrasound-guidance for placement of the PVB, which is a relatively simple technique with a
      well-defined end-point. The investigators have been using 0.2% ropivacaine, which was only
      mentioned in one study of the meta-analysis and was used with a multiple injection technique.
      The majority of studies used 0.5% bupivacaine, and most of these studies used PVB as the sole
      anesthetic technique. The next most common local anesthetic used was ropivacaine 0.5%, and
      this was more frequently used with multi-level injections. As the investigators use a single
      level injection in combination with a GA, these studies are not completely relevant to our
      current practice.

      In this study, the investigators will compare PVB using Ropivacaine 0.2% combined with a GA,
      to GA alone with systemic analgesia.

      Purpose The purpose of this study is to compare GA with systemic analgesia to GA with PVB.
      The parameters examined will be pain scores, perioperative opioid analgesia requirement, and
      PONV. Complications of PVB will also be examined.

      Hypothesis GA plus PVB will reduce pain scores at rest and on movement, the need for rescue
      analgesia, and the incidence of PONV.

      Study population:

      Patients with Breast Cancer listed for surgery at the University Hospital of Alberta and the
      Cross Cancer Hospital. The study will commence following ethical approval.

      Power calculations are required to determine recruitment numbers.

      Methods:

      The study population will be identified by the breast surgeons in their clinic, and potential
      recruits will be provided with information regarding the study protocol and techniques on
      that day. Patient consent will be obtained by the investigating team (study coordinator or
      anesthesiologist) on the day of surgery. Randomisation of participants will also occur at
      this time.

      For those randomised to the PVB group, a block will be placed under sedation by one of the
      Acute Pain Service experienced in paravertebral blocks. The sham block group will receive
      some subcutaneous saline under ultrasound guidance, mild sedation and local anesthetic skin
      infiltration. All patients will receive a standard GA and post-operative protocol.

      Patients who do not wish to enrol in the study will receive a general anesthetic plus
      appropriate analgesia according to the operating room anesthesiologist. No data will be
      recorded, apart from the fact that they declined to take part in the study.

      Primary outcome measures:

      1. Post-operative analgesia requirement

      Secondary outcome measures:

        1. Maximum pain score in the 24 hours following surgery

        2. Incidence of PONV requiring additional treatment.

        3. Maximum pain score in recovery at rest and on shoulder abduction

        4. Incidence of perioperative complications

        5. Intraoperative opioid requirement

      Safety Concerns:

      Paravertebral blocks have been used for many years. Major complications are rare. The
      investigators hypothesise that ultrasound should reduce these complications further as
      anatomical structures are directly visualized.

      Major concerns:

        1. Pleural puncture and pneumothorax

        2. Paravertebral hematoma

        3. Intrathecal local anesthetic injection

        4. Local anesthetic toxicity

        5. Paravertebral infection

      Minor concerns:

        1. Block failure

        2. Epidural spread of local anaesthetic

        3. Low blood pressure

        4. Horner's Syndrome

        5. Injection site hematoma

      Study Protocol

        1. Paravertebral block The patient will be reviewed by the study investigator then moved to
           the block area.

           Paravertebral block will be sited following intravenous access, commencement of IV
           crystalloid, and standard patient monitoring. A time out will confirm side of surgery
           which will be marked.

           Sedation and oxygen will be commenced prior to insertion of the block. The patient will
           be positioned in the seated position with the side of surgery clearly marked. The level
           between the transverse processes of T2 and T3 will be identified using ultrasound, then
           injection of 1% lidocaine to skin. Tissue movement and hydrolocation will confirm block
           needle position, with anterior movement of the pleura being the end point. Once this is
           reached, 20cc of ropivacaine 0.2% will be injected. The patients will progress to the
           standard anesthetic protocol.

        2. Sham block The patient will be taken to the block area, where the IV and monitors will
           be connected as usual. Sedation and oxygen will be commenced. The sham block will occur
           as described for the true paravertebral block, including injection of lidocaine to
           anesthetize the skin, except that a small amount of normal saline (volume of which will
           be left to the anesthesiologist's discretion) will be injected subcutaneously instead of
           injection of ropivacaine next to the nerve.

           On the operating table, routine plus Bispectral (BIS) monitoring will be attached. If no
           midazolam has been administered, 0.03mg/kg will be given intravenously (IV). Fentanyl 1
           microgram per kilogram IV will be given. Propofol will be titrated to allow insertion of
           a laryngeal mask airway (LMA), unless intubation is necessary. This will be at the
           discretion of the operating room anesthetist. Propofol via pump will be given at
           200mcg/kg/min, aiming for a BIS score between 35 and 50. Phenylephrine or ephedrine can
           be titrated as necessary to maintain a mean arterial blood pressure above 60, or greater
           than 75% of the starting mean pressure. Spontaneous ventilation with pressure support
           will be used to maintain an end tidal carbon dioxide level of less than 50mmHg. Fentanyl
           (25mcg boluses) will be titrated to a respiratory rate of 8 - 15 breaths per minute.
           Ketorolac 15mg and Ondansetron 4mg IV will be given unless contra-indicated.

        3. Post-operative Protocol

           All patients will receive standard post-operative orders:

           Patients will receive tramacet 3 tablets PO. Morphine 2mg IV will be given every 5
           minutes as required for pain reported on the Numeric Rating Scale (NRS) of greater than
           5. If intolerant of morphine, hydromorphone 0.4mg IV will be used. Further Ondansetron
           4mg followed by 2 doses of Dimenhydrinate 25mg will be given for nausea and/or vomiting.
           Oxygen will be used to maintain saturations greater than 93%.

           Acetaminophen 975mg 6 hourly and Ibuprofen 400mg with meals three times daily will be
           given.

           Failure of this regime to control pain will trigger the addition of rescue analgesia.

           Rescue analgesia:

           Tramadol - 50 - 100mg po Q6h prn Oxycodone 5 - 10mg po Q3h prn Hydromorphone - 1mg sc
           Q2h PRN The patients will be assessed prior to PARR discharge regarding their pain
           scores at rest and on movement, and again on the morning following surgery.

        4. Data Collection Data will be collected on a study sheet. Information will be kept
           confidential with no patient identifiers on the form, apart from a study number. This
           will reference a list kept securely by the investigators containing the patients' ULI
           numbers.

      The pre- and intra-operative data recorded will be: demographic (age, weight, height), the
      surgical procedure, the amount of fentanyl, ephedrine and phenylephrine and propofol used.

      The recovery data recorded will be: the amount of morphine or hydromorphone required, any
      anti-emetics given, the maximum pain score in recovery at rest and on shoulder abduction.

      After discharge from recovery, the data recorded will be: anti-emetic use, rescue analgesia
      use, maximum pain score in the first 24 hours at rest and on movement.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative analgesia consumption</measure>
    <time_frame>24 hours post-surgery</time_frame>
    <description>Amount of morphine consumed in the 24 hours following surgery will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative pain</measure>
    <time_frame>24 hours post-surgery</time_frame>
    <description>Pain in the 24 hours following surgery will be assessed using a VAS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea/vomiting</measure>
    <time_frame>24 hours post-surgery</time_frame>
    <description>Incidence of nausea and vomiting in the 24 hours following surgery will be recorded on a 4-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain upon movement</measure>
    <time_frame>Within half an hour of return to recovery room</time_frame>
    <description>Maximum pain score will be recorded in recovery at rest and on shoulder abduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative opioid requirement</measure>
    <time_frame>During surgery</time_frame>
    <description>Opioid consumption during surgery will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Nerve Block</condition>
  <arm_group>
    <arm_group_label>GA + sham block</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive general anesthetic plus a sham paravertebral block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA + paravertebral block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive general anesthetic plus a paravertebral block</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>GA + paravertebral block</intervention_name>
    <description>20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block</description>
    <arm_group_label>GA + paravertebral block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>GA + sham block</intervention_name>
    <description>Injection of 1 cc saline subcutaneously</description>
    <arm_group_label>GA + sham block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years of age

          -  Listed for Total Mastectomy +/- Axillary Node Dissection, or Partial Mastectomy

        Exclusion Criteria:

          -  Patient refusal or inability to give informed consent

          -  Any contraindication for paravertebral blockade: coagulopathy, severe respiratory
             disease, local infection, untreated severe hypovolemia

          -  Allergy to propofol, severe egg allergy, or allergy to local anaesthetic agents

          -  Mastectomy plus flap reconstruction

          -  Bilateral procedures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ban C Tsui, MD</last_name>
    <phone>780-407-8604</phone>
    <email>btsui@ualberta.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsui</last_name>
      <email>btsui@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Ban Tsui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Green, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Cameron, MB ChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 2008 Aug 19;99(4):604-10. doi: 10.1038/sj.bjc.6604534.</citation>
    <PMID>18682712</PMID>
  </reference>
  <reference>
    <citation>Poleshuck EL, Katz J, Andrus CH, Hogan LA, Jung BF, Kulick DI, Dworkin RH. Risk factors for chronic pain following breast cancer surgery: a prospective study. J Pain. 2006 Sep;7(9):626-34.</citation>
    <PMID>16942948</PMID>
  </reference>
  <reference>
    <citation>GÃ¤rtner R, Kroman N, Callesen T, Kehlet H. Multimodal prevention of pain, nausea and vomiting after breast cancer surgery. Minerva Anestesiol. 2010 Oct;76(10):805-13.</citation>
    <PMID>20935616</PMID>
  </reference>
  <reference>
    <citation>Karmakar MK. Thoracic paravertebral block. Anesthesiology. 2001 Sep;95(3):771-80. Review.</citation>
    <PMID>11575553</PMID>
  </reference>
  <reference>
    <citation>Schnabel A, Reichl SU, Kranke P, Pogatzki-Zahn EM, Zahn PK. Efficacy and safety of paravertebral blocks in breast surgery: a meta-analysis of randomized controlled trials. Br J Anaesth. 2010 Dec;105(6):842-52. doi: 10.1093/bja/aeq265. Epub 2010 Oct 14. Review. Erratum in: Br J Anaesth. 2013 Sep;111(3):522.</citation>
    <PMID>20947592</PMID>
  </reference>
  <reference>
    <citation>Shkol'nik LD, Vasil'ev VIu, Soboleva LV. [Multi-injection thoracic paravertebral anesthesia during breast cancer operations]. Anesteziol Reanimatol. 2006 Jul-Aug;(4):80-5. Russian.</citation>
    <PMID>17061598</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2013</study_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

